

RECEIVED
CENTRAL FAX CENTER

OCT 27 2003

PATENT

Appl. No. 09/832,510
Amdt. dated 10/27/2003
Amendment under 37 CFR 1.116 Expedited Procedure



Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-6 (Canceled).

7. (Previously presented) A method for detecting a nucleic acid in a biological sample, wherein the nucleic acid encodes a peptide capable of specifically binding to a Lym-1 antibody, the method comprising the following steps, in the following order:

(a) contacting the sample with an oligonucleotide primer pair capable of amplifying a subsequence of an MHC nucleic acid, which subsequence encodes a polypeptide having a sequence comprising R₁ - R₂ - R₃ - R₄ - R₅ - R₆ - R₇ - R₈ - R₉ - R₁₀ - R₁₁ - R₁₂ - R₁₃ - R₁₄ - R₁₅ - R₁₆, wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ and R₄ are members independently selected from the group consisting of all amino acids; R₅ is Ala, Glu, Asp, Val, Leu or Ile; R₆ and R₇ are members independently selected from the group consisting of all amino acids; R₈ is Thr; R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, and R₁₅ are members independently selected from the group consisting of all amino acids; and, R₁₆ is Val (SEQ ID NO:2),

- (b) amplifying the nucleic acid; and
- (c) detecting the amplified nucleic acid.

8. (Previously presented) The method of claim 7, wherein the MHC nucleic acid is HLA-DR 10.

9. (Previously presented) The method of claim 7, wherein the subsequence encodes a peptide wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ is Arg; R₄ is Ala; R₅ is Ala; R₆ is Val; R₇ is Asp; R₈ is Thr; R₉ is Tyr; R₁₀ is Cys; R₁₁ is Arg; R₁₂ is His; R₁₃ is Asn; R₁₄ is Tyr; R₁₅ is Gly, and R₁₆ is Val (SEQ ID NO:2).

Appl. No. 09/832,510
Amdt. dated 10/27/2003
Amendment under 37 CFR 1.116 Expedited Procedure

PATENT

10. (Original) The method of claim 7, wherein the biological sample comprises a B cell.

11. (Original) The method of claim 10, wherein the B cell is a B lymphocytic non-Hodgkin's lymphoma cell.

12. (Original) The method of claim 11, wherein the non-Hodgkin's lymphoma cell is selected from the group consisting of a B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CCL/SLL) cell, a lymphoplasmacytoid lymphoma (LPL) cell, a follicular lymphoma (FL) cell, a mucosa-associated lymphoid tissue lymphoma (MALT) cell, a splenic lymphoma with villous lymphocytes (SLVL) cell and a mantle cell lymphoma cell.

13. (Original) The method of claim 7, wherein the biological sample is a body fluid sample or a biopsy sample.

14. (Original) The method of claim 13, wherein the body fluid sample is a blood sample.

15. (Previously presented) A kit for detecting a nucleic acid in a biological sample, wherein the nucleic acid encodes a peptide capable of specifically binding to a Lym-1 antibody, comprising an oligonucleotide primer pair capable of amplifying a subsequence of an MHC gene or gene product, which subsequence encodes a polypeptide comprising a peptide having a sequence comprising R₁ - R₂ - R₃ - R₄ - R₅ - R₆ - R₇ - R₈ - R₉ - R₁₀ - R₁₁ - R₁₂ - R₁₃ - R₁₄ - R₁₅ - R₁₆, wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ and R₄ are members independently selected from the group consisting of all amino acids; R₅ is Ala, Glu, Asp, Val, Leu or Ile; R₆ and R₇ are members independently selected from the group consisting of all amino acids; R₈ is

Appl. No. 09/832,510
Amdt. dated 10/27/2003
Amendment under 37 CFR 1.116 Expedited Procedure

PATENT

Thr; R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, and R₁₅ are members independently selected from the group consisting of all amino acids; and, R₁₆ is Val (SEQ ID NO:2).

16. (Previously presented) The kit of claim 15, wherein the MHC nucleic acid is HLA-DR 10.

17. (Previously presented) The kit of claim 15, wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ is Arg; R₄ is Ala; R₅ is Ala; R₆ is Val; R₇ is Asp; R₈ is Thr; R₉ is Tyr; R₁₀ is Cys; R₁₁ is Arg; R₁₂ is His; R₁₃ is Asn; R₁₄ is Tyr; R₁₅ is Gly, and R₁₆ is Val (SEQ ID NO:2).

18. (Original) The kit of claim 15, further comprising an instructional material teaching a use of the kit, wherein the instructional material indicates that the kit is used for the detection of nucleic acid encoding a peptide reactive with a Lym-1 antibody and that the polypeptide is associated with non-Hodgkin's B cell lymphomas.

19 -34. (Canceled)

35. (Currently amended) A method for detecting a nucleic acid in a biological sample, wherein the nucleic acid encodes a peptide capable of specifically binding to a Lym-1 antibody, the method comprising the following steps, performed in the following order:

(a) contacting the sample with an oligonucleotide primer pair capable of amplifying a subsequence of an MHC nucleic acid, which subsequence encodes a polypeptide having a sequence consisting essentially of R₁ - R₂ - R₃ - R₄ - R₅ - R₆ - R₇ - R₈ - R₉ - R₁₀ - R₁₁ - R₁₂ - R₁₃ - R₁₄ - R₁₅ - R₁₆, wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ and R₄ are members independently selected from the group consisting of all amino acids; R₅ is Ala, Glu, Asp, Val, Leu or Ile; R₆ and R₇ are members independently selected from the group consisting of all amino acids; R₈ is Thr; R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, and R₁₅ are members independently selected from the group consisting of all amino acids; and, R₁₆ is Val (SEQ ID NO:2),

(b) amplifying the nucleic acid; and

Appl. No. 09/832,510
Amdt. dated 10/27/2003
Amendment under 37 CFR 1.116 Expedited Procedure

PATENT

(c) detecting the amplified nucleic acid.

36. (Previously presented) A method of claim 35, wherein the MHC nucleic acid is HLA-DR 10.

37. (Previously presented) The method of claim 35, wherein the subsequence encodes a peptide wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ is Arg; R₄ is Ala; R₅ is Ala; R₆ is Val; R₇ is Asp; R₈ is Thr; R₉ is Tyr; R₁₀ is Cys; R₁₁ is Arg; R₁₂ is His; R₁₃ is Asn; R₁₄ is Tyr; R₁₅ is Gly, and R₁₆ is Val (SEQ ID NO:2).

38. (Previously presented) The method of claim 35, wherein the biological sample comprises a B cell.

39. (Previously presented) The method of claim 38, wherein the B cell is a B lymphocytic non-Hodgkin's lymphoma cell.

40. (Previously presented) The method of claim 39, wherein the non-Hodgkin's lymphoma cell is selected from the group consisting of a B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CCL/SLL) cell, a lymphoplasmacytoid lymphoma (LPL) cell, a follicular lymphoma (FL) cell, a mucosa-associated lymphoid tissue lymphoma (MALTL) cell, a splenic lymphoma with villous lymphocytes (SLVL) cell and a mantle cell lymphoma cell.

41. (Previously presented) The method of claim 35, wherein the biological sample is a body fluid sample or a biopsy sample.

42 (Previously presented) The method of claim 41, wherein the body fluid sample is a blood sample.

Appl. No. 09/832,510
Amdt. dated 10/27/2003
Amendment under 37 CFR 1.116 Expedited Procedure

PATENT

43. (Previously presented) A kit for detecting a nucleic acid in a biological sample, wherein the nucleic acid encodes a peptide capable of specifically binding to a Lym-1 antibody, comprising an oligonucleotide primer pair capable of amplifying a subsequence of an MHC gene or gene product, which subsequence encodes a polypeptide consisting essentially of a sequence comprising R₁ - R₂ - R₃ - R₄ - R₅ - R₆ - R₇ - R₈ - R₉ - R₁₀ - R₁₁ - R₁₂ - R₁₃ - R₁₄ - R₁₅ - R₁₆, wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ and R₄ are members independently selected from the group consisting of all amino acids; R₅ is Ala, Glu, Asp, Val, Leu or Ile; R₆ and R₇ are members independently selected from the group consisting of all amino acids; R₈ is Thr; R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, and R₁₅ are members independently selected from the group consisting of all amino acids; and, R₁₆ is Val (SEQ ID NO:2).

44. (Previously presented) The kit of claim 43, wherein the MHC nucleic acid is HLA-DR 10.

45. (Previously presented) The kit of claim 43, wherein R₁ is Gln, Lys, or Arg; R₂ is Arg; R₃ is Arg; R₄ is Ala; R₅ is Ala; R₆ is Val; R₇ is Asp; R₈ is Thr; R₉ is Tyr; R₁₀ is Cys; R₁₁ is Arg; R₁₂ is His; R₁₃ is Asn; R₁₄ is Tyr; R₁₅ is Gly, and R₁₆ is Val (SEQ ID NO:2).